Boardroom Alpha
Boardroom Alpha
ASMB · Additional Proxy Materials (DEFA14A) · Filed April 22, 2026

Assembly Biosciences Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 22, 2026
Ticker
ASMB
Accession
0001193125-26-170508
Boardroom Alpha · Filing insights

Assembly Biosciences board urges voting For all proposals, including director elections and stock plan increases.

About Assembly Biosciences Inc
Market cap
$389M
1Y TSR
+72.0%
3Y TSR
+30.2%
Board grade
C+
Sector
Healthcare
CEO
Jason A Okazaki
Last annual meeting: Jun 4, 2026 · View full Assembly Biosciences Inc profile →
DEFA14A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934 (Amendment No. )

 

Filed by the Registrant

 

Filed by a party other than the Registrant

 

CHECK THE APPROPRIATE BOX:

 

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material under § 240.14a‑12

 

img79725823_0.jpg

 

Assembly Biosciences, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

 

PAYMENT OF FILING FEE (CHECK ALL BOXES THAT APPLY):

No fee required

Fee paid previously with preliminary materials

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

 


img79725823_1.jpg

Your Vote Counts! ASSEMBLY BIOSCIENCES, INC. 2026 Annual Meeting Vote by June 3, 2026 11:59 PM EDT assemblybio ASSEMBLY BIOSCIENCES, INC. TWO TOWER PLACE, 7TH FLOOR SOUTH SAN FRANCISCO, CA 94080 You invested in ASSEMBLY BIOSCIENCES, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 4, 2026. Get informed before you vote View the Notice of Assembly Biosciences, Inc.’s 2026 Annual Meeting of Stockholders and Proxy Statement and Annual Report for the fiscal year ended December 31, 2025 online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 21, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.comControl # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 4, 2026 8:00 A.M. PDT Virtually at: www.virtualshareholdermeeting.com/ASMB2026*Please check the meeting materials for any special requirements for meeting attendance.


img79725823_2.jpg

Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting Items 1. Election of Directors. Nominees: 1a. Anthony E. Altig 1b. Tomas Cihlar, Ph.D. 1c. Gina Consylman 1d. Robert D. Cook II 1e. Sir Michael Houghton, Ph.D. 1f. Lisa R. Johnson-Pratt, M.D. 1g. Susan Mahony, Ph.D. 1h. John G. McHutchison, A.O., M.D. 1i. Jason A. Okazaki 2. Approval, on a non-binding advisory basis, of our named executive officers’ compensation. 3. Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. 4. Approval of an amendment to our Amended and Restated 2018 Stock Incentive Plan to increase the number of shares reserved for issuance thereunder by 1,200,000 shares. 5. Approval of an amendment to our Second Amended and Restated 2018 Employee Stock Purchase Plan to increase the authorized number of shares reserved for issuance thereunder to 515,000 shares. NOTE: Your proxy holder will also vote in their discretion upon such other matters that may properly come before the meeting and any adjournment or postponement thereof. Board Recommends For For For For For For For For For For For For For Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.


From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Assembly Biosciences Inc (ASMB)

Reference

Frequently asked questions

When did Assembly Biosciences Inc file this DEFA14A?
Assembly Biosciences Inc (ASMB) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 22, 2026. The accession number assigned by EDGAR is 0001193125-26-170508.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Assembly Biosciences board urges voting For all proposals, including director elections and stock plan increases. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Assembly Biosciences Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Assembly Biosciences Inc has filed under CIK 1426800, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer